This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q07.0 (Arnold-Chiari syndrome) | Special Copayment Reduction: V143 (rare disease) |
| B. Synonyms | Arnold-Chiari syndrome |
| C. Adult onset | Likelihood of first presentation in adulthood: moderate — Chiari type I (cerebellar tonsillar descent ≥5 mm, without hydrocephalus or myelomeningocele) commonly remains asymptomatic in childhood and is first diagnosed in adults (mainly in their 20s–40s) with headache, neck pain, and upper limb abnormalities. Chiari type II (with spina bifida) is mainly diagnosed in the neonatal period, but adult presentation of Chiari I is clinically important. |
| 1. History | Classification described by Cleland in 1883 and Chiari in 1891. Arnold contributed to the formalization of Chiari II. The Chiari I–IV classification is currently the standard. Diagnosis rates surged after MRI became widespread. |
| 2. Causes | Chiari I: insufficient posterior fossa volume (mesodermal insufficiency). Chiari II: CSF leakage with spina bifida → underdevelopment of the posterior fossa. Genetics, CSF dynamics, craniospinal pressure imbalance. |
| 3. Genetics | Mostly sporadic. Some familial (presumed autosomal dominant). May accompany connective tissue disorders (EDS, Marfan). In familial studies of Chiari I, candidate genes related to specific cerebellar–spinal levels are under study. |
| 4. General epidemiology | Population prevalence of Chiari I about 0.5–3.5% (MRI-based). Chiari II accompanies about 90–95% of patients with spina bifida. In Korea, diagnoses of adult Chiari I are increasing since MRI became widespread. |
| 5. Pathophysiology | Insufficient posterior fossa volume → herniation of the cerebellar tonsils through the foramen magnum → impaired CSF circulation → syringomyelia and hydrocephalus. Changes in pressure at the craniospinal junction and disruption of the CSF pulsation. |
| 6. Symptoms | Headache (Valsalva-induced, occipital), neck pain, dizziness, dysphagia, upper limb paresthesia and weakness, dissociated sensory loss related to syringomyelia. Chiari II: complex symptoms with spina bifida. |
| 7. Signs | Occipital tenderness, abnormal limb strength and reflexes, nystagmus (downbeat nystagmus), vocal cord paralysis (Chiari II), cape-like sensory loss with syringomyelia. Cerebellar tonsillar descent confirmed on MRI. |
| 8. Screening | Brain MRI (sagittal) for headache, neck pain, or upper limb symptoms. Head MRI to evaluate Chiari II in all patients with spina bifida. Consider MRI screening when there is a family history. |
| 9. Diagnosis | Brain and cervical spine MRI (sagittal T1/T2): measurement of cerebellar tonsillar descent, effacement of the cisterna magna, syringomyelia, assessment of ventricular size. CSF flow assessment by phase-contrast MRI. Analysis of posterior fossa volume by craniometry. |
| 10. Treatment | Symptomatic Chiari I: suboccipital decompression (suboccipital craniectomy) ± duraplasty. Asymptomatic or mild: observation. With syringomyelia, reduction of the syrinx is expected after decompression. Chiari II: treatment of spina bifida takes priority. |
| 11. Prognosis | Improvement of headache and neck pain after surgery in about 70–80%. Syringomyelia shrinks or stabilizes after surgery. Complete recovery from existing neurological damage is limited. Reoperation needed in about 10–15% on long-term follow-up. |
| 12. Prevention | No specific primary prevention. Spina bifida-related Chiari II is indirectly prevented by folic acid supplementation. Early MRI when symptoms appear prevents diagnostic delay. Regular postoperative MRI follow-up. |
| 13. References | Milhorat TH et al. Neurosurgery 1999; Bhimani S et al. Eur Spine J 2022, and 8 others |
The history of Arnold-Chiari syndrome, or Chiari malformation, begins in European neuropathology in the late 19th century. In 1883, the Scottish physician John Cleland first described a brain malformation in which the cerebellar tonsils and brainstem descend into the foramen magnum, but his report did not attract much attention at the time.
It was the Austrian pathologist Hans Chiari (1851–1916) who systematically classified and named this malformation. Chiari classified cerebellar malformations into three types in 1891 and later added a fourth type in 1895. The German pathologist Julius Arnold (1835–1915) described a case in 1894 in which cerebellar tissue herniated into the spinal canal, contributing to the formalization of Chiari type II. In the early 20th century, the German-speaking world began combining the names of these two scholars as the 'Arnold-Chiari malformation', but it is now recognized that Arnold's contribution was more limited than Chiari's, and the name 'Chiari malformation' is preferred.
The introduction of CT (1971) and MRI (1984) revolutionized the diagnosis of Chiari malformation. In particular, high-resolution sagittal MRI images made it possible to measure the degree of cerebellar tonsillar descent accurately, greatly increasing the frequency of diagnosis of Chiari type I. Before MRI became widespread, it was diagnosed only by invasive myelography in symptomatic patients or at postmortem autopsy, but after MRI, incidental findings in asymptomatic adults increased. Currently, Chiari type I is reported to be identified on MRI in about 0.5–3.5% of the population.
The modern classification of Chiari malformation is standardized as Types I–IV. Type I is isolated descent of the cerebellar tonsils through the foramen magnum (≥5 mm); Type II is descent of the cerebellar tonsils and brainstem + spina bifida; Type III is accompanied by a high cervical cele (cervical meningocele/encephalocele); and Type IV is cerebellar hypoplasia. Clinically, the most common and important are Type I and Type II. In Korea as well, diagnoses of adult Chiari I have increased since MRI became widespread, and when registered under rare disease Special Copayment Reduction V143, a reduced copayment benefit is provided. Recently, new classification proposals such as Chiari type 1.5 (including tonsillar + brainstem descent) and type 0 (only impaired CSF flow without tonsillar descent) are also under discussion.
The causes of Chiari malformation differ by type. The developmental mechanisms of Chiari types I and II are understood to be fundamentally different.
Causes of Chiari type I — insufficient posterior fossa volume: the most widely accepted theory is reduced bony volume of the posterior cranial fossa due to mesodermal insufficiency. When the volume of the posterior fossa is insufficient to accommodate the cerebellum, the cerebellar tonsils herniate extradurally through the foramen magnum. Causes of posterior fossa bony abnormalities include occipital hypoplasia, basilar invagination, and latent skull base anomalies. Some studies have confirmed by measurement that the posterior fossa volume of patients with Chiari I is significantly smaller than that of normal controls.
A cerebrospinal fluid (CSF) dynamics theory has also been proposed. It holds that abnormal transmission of the CSF pulsation repeatedly pushes the cerebellar tonsils toward the foramen magnum, causing or worsening herniation. This theory is consistent with the clinical observation that, in some patients, syringomyelia improves with control of CSF pressure alone without surgical decompression.
Causes of Chiari type II — association with spina bifida: Chiari type II is almost always accompanied by spina bifida, including myelomeningocele. Its developmental mechanism is explained by the 'hydrodynamic theory'. When the myelomeningocele is open in spina bifida, CSF continuously leaks through the cele during fetal life, and as a result the posterior fossa, with lowered CSF pressure, fails to develop normally and becomes volume-deficient. Consequently, the posterior fossa is small and the cerebellar tonsils and brainstem descend. The MOMS trial confirmed that fetal in utero spinal closure reduces the severity of Chiari II, supporting this theory.
Association with connective tissue disorders: Chiari I has been reported in patients with connective tissue disorders such as Ehlers-Danlos syndrome (EDS) and Marfan syndrome. This is explained by laxity of the craniocervical ligaments causing instability of the posterior fossa–spinal canal junction and worsening cerebellar tonsillar descent. The co-occurrence of basilar invagination and Chiari I is also common.
Familial clustering of Chiari type I is not uncommonly reported, and an autosomal dominant inheritance pattern is suggested in some families. However, because penetrance is low and expressivity is variable, it is likely to have a multifactorial genetic architecture not explained by a single-gene defect. Several studies of familial Chiari I have reported linkage to some chromosomal regions such as 9q22 and 15q21-22, but the causative gene has not yet been identified.
Genetic disorders associated with Chiari I include skeletal dysplasia, craniosynostosis, and connective tissue disorders. Posterior fossa abnormalities have also been reported in patients with acromegaly, rickets, and Alagille syndrome. In craniosynostosis, reduced intracranial volume can cause herniation of the cerebellar tonsils. Chiari I has been reported in patients with EDS (especially hypermobile EDS, hEDS), and EDS-related genes (COL5A1, COL3A1, TNXB, etc.) may be indirectly involved. An association between Marfan syndrome (FBN1 gene) and Chiari I is also known from case reports.
Because Chiari type II accompanies spina bifida (multifactorial inheritance), it has an indirect association with NTD-related genes (MTHFR, VANGL1/2, the PCP pathway). The risk of spina bifida + Chiari II may be increased in carriers of the MTHFR C677T TT genotype. The familial recurrence risk follows the recurrence risk of spina bifida (about 3–5%).
Genetic counseling: when familial Chiari I is suspected, brain MRI screening of first-degree relatives is considered regardless of symptoms. When a connective tissue disorder (EDS, Marfan) is present, genetic evaluation for that disorder is performed concurrently. In general, when counseling on familial recurrence risk for sporadic Chiari I, it is reasonable to advise a risk of around 5%.
The prevalence of Chiari malformation differs according to type and diagnostic criteria. For Chiari type I, population-based studies since MRI became widespread report a prevalence of up to 0.5–3.5%, many of which are incidentally found asymptomatic cases. The prevalence of symptomatic Chiari I is estimated at about 0.5–3 per 100,000 population, and it is diagnosed slightly more often in women. Chiari type II accompanies about 90–95% of patients with spina bifida including myelomeningocele, so it is proportional to the incidence of spina bifida.
Chiari I is found at all ages, but symptom onset mainly occurs in childhood or early adulthood (20s–40s). In adults, Chiari I is commonly found on MRI of patients presenting with headache, neck pain, and upper limb abnormalities. In children, it often presents with headache, vomiting, dysphagia, growth disturbance, and the like. Syringomyelia accompanies about 30–70% of patients with Chiari I, and the larger the syrinx, the greater the likelihood of neurological symptoms.
Epidemiology in Korea: in Korea, diagnoses of adult Chiari I are increasing with improved MRI access and expansion of health screening programs. According to Health Insurance Review & Assessment Service (HIRA) data, the number of patients treated for Chiari malformation (Q07.0) has been increasing since the 2010s. Criteria distinguishing incidentally found asymptomatic Chiari I from symptomatic forms are clinically important; a cerebellar tonsillar descent of 5 mm is used as the conventional cutoff, but treatment decisions are not made on this criterion alone. Patients registered under Special Copayment Reduction V143 receive the rare disease reduced copayment benefit.
Because the rate of accompanying syringomyelia in Chiari malformation is high, evaluating the entire spinal cord with MRI for a syrinx at the time of Chiari diagnosis is standard. The size and extent of the syringomyelia are important factors in determining surgical indications and predicting prognosis. The risk of symptom onset in patients with Chiari I without syringomyelia is relatively low, but the presence of a syrinx or greater cerebellar tonsillar descent increases the risk of symptom onset and progression.
The core of the pathophysiology of Chiari malformation is reduced posterior fossa volume and the resulting herniation of the cerebellar tonsils through the foramen magnum. This herniation obstructs CSF circulation and consequently causes various neurological complications.
Insufficient posterior fossa volume and cerebellar tonsillar herniation: the normal posterior fossa has sufficient volume to accommodate the cerebellum, pons, and medulla oblongata. In Chiari I, the bony volume of the posterior fossa is smaller than normal, so the cerebellar tonsils herniate subdurally through the foramen magnum. The herniated cerebellar tonsils compress the area around the foramen magnum and obstruct the flow of CSF that should normally pass through the foramen magnum (mainly pulsatile flow synchronized with the heartbeat). This impaired CSF flow is the pathophysiological basis of syringomyelia and hydrocephalus.
Mechanism of syringomyelia: because of impaired CSF flow at the foramen magnum, pressure within the spinal canal rises sharply during Valsalva maneuvers (sneezing, coughing, straining). This pressure wave is transmitted to the spinal cord parenchyma, causing fluid accumulation in the central spinal cord (around the central canal), which gradually expands to form a syrinx. As the syrinx enlarges, the pain and temperature fibers in the spinal cord (crossing to the lateral spinothalamic tract) are selectively damaged, producing 'cape-like' dissociated sensory loss.
Pathophysiology of Chiari II: in spina bifida, fetal CSF leakage into the myelomeningocele impairs posterior fossa development, causing a small posterior fossa and the Chiari II malformation. The herniated cerebellar tonsils and brainstem block the foramen magnum, causing hydrocephalus, and the herniated brainstem directly compresses respiratory, swallowing, and vocal cord functions, which can cause life-threatening complications such as apnea, dysphagia, and vocal cord paralysis.
Craniospinal pressure imbalance: there is also a theory that a pressure imbalance between the cranial cavity and the spinal canal is involved in the progression of Chiari I. When intracranial pressure is relatively high (high cerebral venous pressure) or pressure within the spinal canal is relatively low (reduced elasticity of the spinal dura), the cerebellar tonsils are subjected to continuous pressure toward the spinal canal. This theory explains in particular the mechanism by which ligamentous laxity in patients with EDS worsens craniospinal junction instability and causes Chiari I.
The symptoms of Chiari malformation vary according to type, degree of cerebellar tonsillar descent, presence of accompanying syringomyelia, and presence of hydrocephalus.
Symptoms of Chiari type I: the most characteristic symptom is Valsalva-induced headache. Characteristic is a headache that arises in the occipital region on coughing, sneezing, straining, or laughing and radiates to the neck and arms. This headache peaks within seconds to minutes immediately after the Valsalva maneuver and then subsides. Neck pain and stiffness may accompany it. Dizziness, tinnitus, hearing loss, nystagmus (downbeat nystagmus), diplopia, dysphagia, and nausea and vomiting may appear. Paresthesia of the arms and hands (numbness, burning sensation), muscle weakness, ataxia, and gait instability appear. With accompanying syringomyelia, cape-like dissociated sensory loss (loss of pain and temperature sensation in the arms, shoulders, and chest, with preserved touch and proprioception) and atrophy of the intrinsic hand muscles are added.
Symptoms of Chiari type II: in newborns, apneic spells, cyanosis, dysphagia, vocal cord paralysis (high-pitched cry, inspiratory stridor), limb weakness, and bulbar symptoms due to brainstem compression appear. Symptoms of increased intracranial pressure due to hydrocephalus (bulging anterior fontanelle, sunset eye sign) accompany them. Lower-limb paralysis and bladder and bowel dysfunction due to the spina bifida itself also present in combination.
Asymptomatic Chiari I: some people remain asymptomatic for life even when cerebellar tonsillar descent of 5 mm or more is confirmed on MRI. In prospective cohort studies of the natural history of asymptomatic Chiari I, about 70–80% remained stable without new symptoms, and symptoms developed within a few years in about 10–20%. Therefore, observation rather than surgery is prioritized for asymptomatic Chiari I.
The physical signs of Chiari malformation vary according to type and accompanying complications.
Head and neck signs: tenderness below the occiput, limited neck movement (especially increased pain on flexion), and suboccipital muscle tension may appear. When there is instability of the craniocervical junction (e.g., with EDS), cervical hypermobility is observed.
Cranial nerve signs: downbeat nystagmus is a characteristic neuro-ophthalmological sign of Chiari I, a pattern of slow upward drift, with the eyes moving opposite to the direction of gaze, followed by a fast downward return. Diplopia, abnormal eye movements, hearing loss, and tinnitus may appear. In Chiari II, a high-pitched cry, dysphagia, and respiratory failure due to vocal cord paralysis are observed.
Limb and cerebellar signs: upper limb weakness, atrophy of the intrinsic hand muscles, ataxia (impaired rapid alternating movements of both hands, unstable tandem gait), and a wide-based gait appear. With accompanying syringomyelia, cape-like dissociated sensory loss of the arms and shoulders (loss of pain and temperature sensation, preserved touch) is confirmed on examination. Lower motor neuron signs (weakness, decreased reflexes) and upper motor neuron signs (spasticity, Babinski reflex) may coexist.
Imaging signs: on sagittal brain MRI, descent of the cerebellar tonsils 5 mm or more below the foramen magnum is the key diagnostic sign. Effacement or reduction of the cisterna magna is observed. Phase-contrast MRI (PC-MRI) shows reduced or absent CSF flow around the foramen magnum. Spinal MRI shows a syrinx and T2 hyperintensity. Craniometry can quantify reduced posterior fossa volume.
There is no general population screening for Chiari malformation. The main diagnostic pathway is symptom-based imaging.
Symptom-based MRI: when there are symptoms suggestive of Chiari, such as Valsalva-induced headache, posterior neck pain, upper limb paresthesia and weakness, or incoordination, brain MRI (sagittal T1, T2) is performed. If syringomyelia is suspected, MRI of the entire spinal cord is included. In adult outpatient settings, Valsalva-induced headache is a specific symptom of Chiari I, and MRI is strongly recommended when this complaint is present.
Evaluation of associated conditions in spina bifida patients: in all patients with spina bifida (myelomeningocele), head MRI after birth evaluates for Chiari II malformation and hydrocephalus. Because Chiari II is present in about 90–95% of spina bifida patients, testing is done without exception.
Familial Chiari I screening: some institutions consider brain MRI screening of first-degree relatives (especially parents and siblings) of Chiari I patients regardless of symptoms. In some studies, tonsillar descent on MRI was found in about 12–23% of family members of Chiari I patients.
Evaluation of associated connective tissue disease: in patients diagnosed with EDS or Marfan syndrome who have posterior neck pain or headache, MRI is performed to differentiate Chiari I from craniocervical instability.
Chiari malformation is diagnosed centered on MRI, through a synthesis of clinical symptoms and imaging findings.
Brain MRI (sagittal): the distance of cerebellar tonsillar descent is measured from McRae's line (the line connecting the anterior and posterior margins of the foramen magnum). Descent of 5 mm or more is the most widely used diagnostic criterion for Chiari I, but even less than 5 mm is clinically significant when there are symptoms with effacement of the cisterna magna, impaired CSF flow, or syringomyelia. In Chiari II, the brainstem (pons, medulla) descends along with the cerebellar tonsils, and a downward-flexed 'kink' appears. Hydrocephalus (lateral ventricular enlargement), effacement of the cisterna magna, and hypoplasia of the tentorium cerebelli are assessed.
Spinal MRI: MRI of the entire spinal cord (cervical to lumbar) is performed to assess the location and size (transverse diameter, length) of the syrinx and spinal cord T2 hyperintensity. The size and extent of the syrinx are associated with surgical indications and prognosis.
Phase-contrast MRI (PC-MRI): a functional imaging technique that quantitatively assesses CSF flow around the foramen magnum. Normally, CSF flows downward through the foramen magnum during cardiac systole and upward during diastole. In Chiari I, reduction or absence of this flow is useful for predicting the likelihood of postoperative recovery.
Craniometric analysis: the posterior fossa volume, tentorial angle, and skull base structure are analyzed to identify the structural cause of Chiari I. The presence of basilar invagination or atlantoaxial subluxation is assessed by CT or MRI.
Electrophysiological testing: brainstem auditory evoked potentials (BAEP), visual evoked potentials (VEP), and SSEP assess sensory pathway function. They are used as preoperative baseline data and also for intraoperative IONM.
Treatment of Chiari malformation is determined by the presence of symptoms, accompanying syringomyelia, hydrocephalus, and neurological progression.
Suboccipital craniectomy (posterior fossa decompression): the main surgical treatment for symptomatic Chiari I. The posteroinferior occipital bone is resected to enlarge the posterior fossa volume and relieve herniation of the cerebellar tonsils through the foramen magnum. A method commonly used adds duraplasty (autologous dura, allograft dura, synthetic material) after dural opening to further enlarge the posterior fossa volume. Tonsillar cauterization or coagulation is additionally performed at some institutions to shrink the cerebellar tonsils directly and secure space. Syringomyelia mostly shrinks or stabilizes with restoration of CSF flow after decompression; a separate syringosubarachnoid shunt is considered when the decompression effect is insufficient.
Treatment of hydrocephalus: if hydrocephalus is present in Chiari II, a ventriculoperitoneal shunt (VP shunt) or endoscopic third ventriculostomy (ETV) is performed. In some Chiari II patients, shunting alone relieves Chiari II complications.
Management of asymptomatic Chiari I: when there is only cerebellar tonsillar descent without symptoms or syringomyelia, clinical and imaging follow-up is recommended rather than surgery. Follow-up intervals are generally clinical examination 1–2 times a year and MRI every 2–3 years. Lifestyle guidance is given to refrain from strenuous Valsalva-inducing activities. Surgery is reconsidered if symptoms appear or the syrinx progresses.
Rehabilitation and pain management: if headache and posterior neck pain persist after surgery, physical therapy, NSAIDs, preventive migraine medications, and trigger point injections are considered. Gabapentinoid drugs may help with pain due to syringomyelia. In patients with cerebellar ataxia, rehabilitation therapy including balance training and gait assistance is provided.
Prognosis after surgery for Chiari malformation varies according to type, kind of symptoms, and degree of preoperative neurological damage. Overall, improvement rates of headache and posterior neck pain after surgical decompression are reported at about 70–80%.
Syringomyelia shrinks or stabilizes in about 60–80% after surgery, and syrinx-related sensory and motor symptoms also partially improve. However, neurological damage from long-standing syringomyelia is difficult to recover from completely after surgery. Incoordination and dysphagia may improve after surgery, but complete recovery is not guaranteed. On long-term follow-up, about 10–15% of patients need reoperation, the main causes being adhesions at the duraplasty site, re-herniation of the cerebellar tonsils, and re-expansion of the syrinx. In Chiari II patients, improvement of medullary symptoms (apnea, vocal cord paralysis) after surgery is reported in about 50–70%. The natural history of asymptomatic Chiari I is mostly stable, with about 70–80% remaining free of new symptoms over 5–10 years of follow-up. Quality of life improves significantly after surgery with reduced headache, recovery of activity, and stabilization of syringomyelia. The effect on life expectancy itself varies with type and complications, but when Chiari I occurs alone in adults, normal life expectancy is possible with appropriate treatment.
No specific primary prevention method for Chiari malformation has been established.
Indirect prevention of Chiari II: Chiari II associated with spina bifida (NTD) can be prevented indirectly by reducing the occurrence of NTD itself through folic acid supplementation before and in early pregnancy. Prescription of high-dose folic acid (5 mg/day) for high-risk groups, prenatal screening (MSAFP, detailed ultrasound), and fetal intrauterine spinal closure (when eligibility criteria are met) are ways to reduce the severity of Chiari II.
Delaying symptom onset in Chiari I (secondary prevention): patients diagnosed with Chiari I are advised to refrain from Valsalva-inducing activities (lifting heavy objects, strenuous anaerobic exercise, exercise involving high-intensity Valsalva maneuvers) to prevent symptom worsening. Regular follow-up MRI detects progression of syringomyelia early so that surgery can be decided in a timely manner. Diagnosis and management of EDS and Marfan syndrome, which affect craniospinal junction stability, may contribute to preventing worsening of Chiari I.
Prevention of surgical complications (tertiary prevention): regular MRI follow-up (at 6 months and 1 year after surgery, then every 2–3 years) is needed to detect postoperative dural adhesions, re-herniation, and re-expansion of the syrinx early. Residual postoperative symptoms are minimized through physical therapy and rehabilitation.